Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
169.94B
Market cap169.94B
Price-Earnings ratio
11.07
Price-Earnings ratio11.07
Dividend yield
3.19%
Dividend yield3.19%
Average volume
37.81M
Average volume37.81M
High today
$39.61
High today$39.61
Low today
$38.17
Low today$38.17
Open price
$38.60
Open price$38.60
Volume
15.63M
Volume15.63M
52 Week high
$88.55
52 Week high$88.55
52 Week low
$35.85
52 Week low$35.85

NVO News

Simply Wall St 7h
Why Hims & Hers Health Is Up 8.4% After Novo Nordisk GLP-1 Partnership Resolution – And What's Next

In February 2026, Hims & Hers Health and Novo Nordisk entered into a partnership allowing Hims to offer branded obesity drugs like Wegovy and Ozempic through it...

Why Hims & Hers Health Is Up 8.4% After Novo Nordisk GLP-1 Partnership Resolution – And What's Next
Investor's Business Daily 9h
Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs

News Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs Licensing Hims and Hers (HIMS) surged late Friday on a report that Novo Nordisk (NVO) w...

Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs
The Motley Fool 15h
Where Will Eli Lilly Stock Be in 10 Years?

Eli Lilly (LLY +0.70%) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs have proven more...

Where Will Eli Lilly Stock Be in 10 Years?

Analyst ratings

59%

of 34 ratings
Buy
35.3%
Hold
58.8%
Sell
5.9%

More NVO News

24/7 Wall St. 15h
Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce

Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce Quick Read Hims & Hers (HIMS) surged 40% in aftermarket trading after falling 77% from its peak....

Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce
The Motley Fool 16h
Can This Next-Gen Obesity Drug Save Novo Nordisk?

Things are going from bad to worse for Novo Nordisk (NVO 1.27%). The Denmark-based drugmaker had already seen its blockbuster weight loss medicine, Wegovy, lose...

Can This Next-Gen Obesity Drug Save Novo Nordisk?
Simply Wall St 1d
Novo Nordisk Faces Securities Probe And GLP-1 Compounding Crackdown

Law firm launches investigation into NYSE:NVO for potential securities violations following a setback in an obesity drug clinical trial. U.S. regulators issue...

Novo Nordisk Faces Securities Probe And GLP-1 Compounding Crackdown
Benzinga 1d
Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report

Novo Nordisk AS (NYSE:NVO) and Hims & Hers Health Inc. (NYSE:HIMS) have reportedly ended their public feud, with the drugmaker deciding to sell its weight-loss...

Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report
Bloomberg 1d
Novo and Hims End Feud, Will Sell Obesity Drugs Together

Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly publ...

Novo and Hims End Feud, Will Sell Obesity Drugs Together
Nasdaq 1d
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?

Key Points Novo Nordisk shares look cheap, but execution and management changes weigh on investor confidence. Eli Lilly’s stronger GLP-1 growth and consistenc...

Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
TipRanks 2d
Novo Nordisk Targets Real-World Heart and Kidney Outcomes for Ozempic in China

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study A Retrospective Database Study to Compare Cardiovascular and Renal Outcomes o...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.